{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T07:10:54Z","timestamp":1780557054357,"version":"3.54.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,24]]},"DOI":"10.7759\/cureus.93104","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T12:59:40Z","timestamp":1758718780000},"source":"Crossref","is-referenced-by-count":1,"title":["The Effects of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on Polycystic Ovarian Syndrome: A Scoping Review"],"prefix":"10.7759","author":[{"given":"Mia","family":"Hudanich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon N","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Marino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne I","family":"Riskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dey256","article-title":"Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"33","author":"Teede HJ","year":"2018","unstructured":"Teede HJ, Misso ML, Costello MF, et al.. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018, 33:1602-18. 10.1093\/humrep\/dey256","journal-title":"Hum Reprod"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13061113","article-title":"Current guidelines for diagnosing PCOS","volume":"13","author":"Christ JP","year":"2023","unstructured":"Christ JP, Cedars MI. Current guidelines for diagnosing PCOS. Diagnostics (Basel). 2023, 13:10.3390\/diagnostics13061113","journal-title":"Diagnostics (Basel)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2010.02.015","article-title":"Variation in metabolic and cardiovascular risk in women with different polycystic ovary syndrome phenotypes","volume":"94","author":"Wiltgen D","year":"2010","unstructured":"Wiltgen D, Spritzer PM. Variation in metabolic and cardiovascular risk in women with different polycystic ovary syndrome phenotypes. Fertil Steril. 2010, 94:2493-6. 10.1016\/j.fertnstert.2010.02.015","journal-title":"Fertil Steril"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-024-01720-3","article-title":"Insulin resistance and insulin secretory defect among Bangalee PCOS women: a case-control study","volume":"24","author":"Nayeem J","year":"2024","unstructured":"Nayeem J, Islam MM, Deeba F, Selim S, Ali L, Kabir Y. Insulin resistance and insulin secretory defect among Bangalee PCOS women: a case-control study. BMC Endocr Disord. 2024, 24:207. 10.1186\/s12902-024-01720-3","journal-title":"BMC Endocr Disord"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1492","article-title":"Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance","volume":"94","author":"Ciaraldi TP","year":"2009","unstructured":"Ciaraldi TP, Aroda V, Mudaliar S, Chang RJ, Henry RR. Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance. J Clin Endocrinol Metab. 2009, 94:157-63. 10.1210\/jc.2008-1492","journal-title":"J Clin Endocrinol Metab"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-023-03487-4","article-title":"Effects and plasma proteomic analysis of GLP-1RA versus CPA\/EE, in combination with metformin, on overweight PCOS women: a randomized controlled trial","volume":"83","author":"Liao M","year":"2024","unstructured":"Liao M, Li X, Zhang H, et al.. Effects and plasma proteomic analysis of GLP-1RA versus CPA\/EE, in combination with metformin, on overweight PCOS women: a randomized controlled trial. Endocrine. 2024, 83:227-41. 10.1007\/s12020-023-03487-4","journal-title":"Endocrine"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12185921","article-title":"Semaglutide treatment of excessive body weight in obese PCOS patients unresponsive to lifestyle programs","volume":"12","author":"Carmina E","year":"2023","unstructured":"Carmina E, Longo RA. Semaglutide treatment of excessive body weight in obese PCOS patients unresponsive to lifestyle programs. J Clin Med. 2023, 12:10.3390\/jcm12185921","journal-title":"J Clin Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00189","article-title":"The effect of exenatide on cardiovascular risk markers in women with polycystic ovary syndrome","volume":"10","author":"Dawson AJ","year":"2019","unstructured":"Dawson AJ, Sathyapalan T, Vince R, Coady AM, Ajjan RA, Kilpatrick ES, Atkin SL. The effect of exenatide on cardiovascular risk markers in women with polycystic ovary syndrome. Front Endocrinol (Lausanne). 2019, 10:189. 10.3389\/fendo.2019.00189","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae319","article-title":"Effects of tirzepatide vs semaglutide on \u03b2-cell function, insulin sensitivity, and glucose control during a meal test","volume":"109","author":"Mather KJ","year":"2024","unstructured":"Mather KJ, Mari A, Heise T, et al.. Effects of tirzepatide vs semaglutide on \u03b2-cell function, insulin sensitivity, and glucose control during a meal test. J Clin Endocrinol Metab. 2024, 109:3046-54. 10.1210\/clinem\/dgae319","journal-title":"J Clin Endocrinol Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2023.08.635","article-title":"Effects of metformin alone versus metformin and tirzepatide on weight loss in patients with polycystic ovarian syndrome (PCOS)","volume":"120","author":"Sassin AM","year":"2023","unstructured":"Sassin AM, Sangi-Haghpeykar H, Aagaard KM, Detti L. Effects of metformin alone versus metformin and tirzepatide on weight loss in patients with polycystic ovarian syndrome (PCOS). Fertil Steril. 2023, 120:E222. 10.1016\/j.fertnstert.2023.08.635","journal-title":"Fertil Steril"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa863","article-title":"Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes","volume":"106","author":"Thomas MK","year":"2021","unstructured":"Thomas MK, Nikooienejad A, Bray R, et al.. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab. 2021, 106:388-96. 10.1210\/clinem\/dgaa863","journal-title":"J Clin Endocrinol Metab"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial","volume":"389","author":"Jastreboff AM","year":"2023","unstructured":"Jastreboff AM, Kaplan LM, Fr\u00edas JP, et al.. Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial. N Engl J Med. 2023, 389:514-26. 10.1056\/NEJMoa2301972","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","volume":"402","author":"Rosenstock J","year":"2023","unstructured":"Rosenstock J, Frias J, Jastreboff AM, et al.. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023, 402:529-44. 10.1016\/S0140-6736(23)01053-X","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000001712","article-title":"Short-term combined treatment with exenatide and metformin for overweight\/obese women with polycystic ovary syndrome","volume":"134","author":"Ma RL","year":"2021","unstructured":"Ma RL, Deng Y, Wang YF, Zhu SY, Ding XS, Sun AJ. Short-term combined treatment with exenatide and metformin for overweight\/obese women with polycystic ovary syndrome. Chin Med J (Engl). 2021, 134:2882-9. 10.1097\/CM9.0000000000001712","journal-title":"Chin Med J (Engl)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.945609","article-title":"Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome","volume":"13","author":"Xing C","year":"2022","unstructured":"Xing C, Zhao H, Zhang J, He B. Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome. Front Endocrinol (Lausanne). 2022, 13:945609. 10.3389\/fendo.2022.945609","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1080\/09513590.2023.2223648","article-title":"Low dose of liraglutide combined with metformin leads to a significant weight loss in Chinese Han women with polycystic ovary syndrome: a retrospective study","volume":"39","author":"Long X","year":"2023","unstructured":"Long X, Liu H, Xiong W, et al.. Low dose of liraglutide combined with metformin leads to a significant weight loss in Chinese Han women with polycystic ovary syndrome: a retrospective study. Gynecol Endocrinol. 2023, 39:2223648. 10.1080\/09513590.2023.2223648","journal-title":"Gynecol Endocrinol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa692","article-title":"Exenatide, metformin, or both for prediabetes in PCOS: a randomized, open-label, parallel-group controlled study","volume":"106","author":"Tao T","year":"2021","unstructured":"Tao T, Zhang Y, Zhu YC, et al.. Exenatide, metformin, or both for prediabetes in PCOS: a randomized, open-label, parallel-group controlled study. J Clin Endocrinol Metab. 2021, 106:e1420-32. 10.1210\/clinem\/dgaa692","journal-title":"J Clin Endocrinol Metab"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1366940","article-title":"The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: a 2-year observational study","volume":"15","author":"Jensterle M","year":"2024","unstructured":"Jensterle M, Ferjan S, Janez A. The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: a 2-year observational study. Front Endocrinol (Lausanne). 2024, 15:1366940. 10.3389\/fendo.2024.1366940","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14944","article-title":"Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity","volume":"25","author":"Jensterle M","year":"2023","unstructured":"Jensterle M, Ferjan S, Le\u017eai\u010d L, So\u010dan A, Gori\u010dar K, Zaletel K, Janez A. Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity. Diabetes Obes Metab. 2023, 25:975-84. 10.1111\/dom.14944","journal-title":"Diabetes Obes Metab"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14056","article-title":"Changes in whole metabolites after exenatide treatment in overweight\/obese polycystic ovary syndrome patients","volume":"91","author":"Tang L","year":"2019","unstructured":"Tang L, Yuan L, Yang G, Wang F, Fu M, Chen M, Liu D. Changes in whole metabolites after exenatide treatment in overweight\/obese polycystic ovary syndrome patients. Clin Endocrinol (Oxf). 2019, 91:508-16. 10.1111\/cen.14056","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2022.04.027","article-title":"Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study","volume":"118","author":"Elkind-Hirsch KE","year":"2022","unstructured":"Elkind-Hirsch KE, Chappell N, Shaler D, Storment J, Bellanger D. Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study. Fertil Steril. 2022, 118:371-81. 10.1016\/j.fertnstert.2022.04.027","journal-title":"Fertil Steril"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00085-7","article-title":"Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial","volume":"10","author":"Heise T","year":"2022","unstructured":"Heise T, Mari A, DeVries JH, et al.. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol. 2022, 10:418-29. 10.1016\/S2213-8587(22)00085-7","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/398477-the-effects-of-glucagon-like-peptide-1-glp-1-receptor-agonists-on-polycystic-ovarian-syndrome-a-scoping-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T12:59:40Z","timestamp":1758718780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/398477-the-effects-of-glucagon-like-peptide-1-glp-1-receptor-agonists-on-polycystic-ovarian-syndrome-a-scoping-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.93104","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,24]]}}}